Avoid the seven most common tissue cross-reactivity planning mistakes, from late starts to unreliable methods, that can put your IND, CTA or first-in-human timeline at risk.
Avoid the seven most common tissue cross-reactivity planning mistakes, from late starts to unreliable methods, that can put your IND, CTA or first-in-human timeline at risk.
Expert guidance on classifying adverse vs. nonadverse nerve fiber degeneration in intrathecal oligonucleotide nonclinical toxicity studies.
Explore how early integration of toxicologic pathology can improve medical device safety, reduce miscommunication, and strengthen regulatory outcomes in device development.
Learn how integrating toxicologic pathology best practices into medical device evaluation can improve biological assessment, strengthen regulatory outcomes, and reduce study risk.
The road to bringing a medical device to market is fraught with potential regulatory pitfalls and decisions that can delay—or even derail—your efforts.
When it comes to preclinical research and clinical trials, the logistics outside the lab are as crucial as the processes and handling of samples inside the lab. In other words, frozen samples must be handled with care and transported in a timely manner to make sure project milestones are reached.
Immunohistochemistry (IHC) and immunofluorescence (IF) are molecular assays that involve the use of antibodies to detect specific proteins within tissues on microscope slides
Good Laboratory Practices (GLP) refers to a system where non-clinical health and safety studies are carried out, planned, monitored, recorded, archived and reported.
513.204.4400
